Abbott initiates CROWN-MV pivotal trial for Cephea device
Abbott has started the CROWN-MV study, a prospective pivotal trial that will enroll up to 585 patients with symptomatic mitral valve disease in the U.S., Canada and Europe. The trial will evaluate the safety and effectiveness of the investigational Cephea Mitral Valve System, a catheter-based replacement option for patients not candidates for surgery or transcatheter repair.
Primary source
Company press release (PR Newswire), October 29, 2026
Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
Read the source: Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease prnewswire.com
Machine-summarized from the source above; not independently reported. How we use automation